

## **Beta-lactoglobulin as** pharmaceutical excipient

Proteins comprise a new group of excipients for preparing amorphous solid dispersions. Beta-lactoglobulin (BLG), the main component in Dispersome formulations, results in superior drug solubility compared to other proteins. Hovione has developed a partnership with Zerion Pharma who has a strong IP portfolio covering protein-based excipients for solid dispersions with patent life beyond 2040.

## Stable formulations with high drug loading

The use of Dispersome® technology enables drug loadings above 50% w/w while maintaining stability and improving API solubility. At a drug loading of 50%, stable amorphous formulations are obtained for more than 80% of all drugs tested.

# Superior outcomes, compatible technology

By increasing drug solubility, the Dispersome® platform aims at improving oral bioavailability and therapeutic outcomes for patients. Dispersome® formulations are compatible with standard pharmaceutical processes and Spray Drying provides a scalable manufacturing

## A safe and manufacturable excipient

We work with world leading suppliers to source and qualify our BLG material, ensuring high quality and large scale supply. BLG is a natural ingredient used in food and nutrition products and is easy to integrate in your existing processes.


dispersome@hovione.com | www.hovione.com

Contact us today to solve your solubility challenges:

Dispersome® formulation achieves a superior dissolution rate and better solubility compared to other solid dispersions when addressing a poorly soluble drug like ZN-X.



Dispersome® formulations result in a substantial solubility increase for most poorly soluble drugs, compared to the crystalline form of the drug.



#### Your preferred solubility partner

We invite you to test the performance of your formulation using Dispersome® Technology. Our partner Zerion has successfully used this technology on multiple drug molecules from pharma companies.